PMID- 24755253 OWN - NLM STAT- MEDLINE DCOM- 20141209 LR - 20141013 IS - 1879-3592 (Electronic) IS - 1383-5718 (Linking) VI - 767 DP - 2014 Jun TI - Genotoxic evaluation of five Angiotesin II receptor blockers: in vivo and in vitro micronucleus assay. PG - 1-7 LID - S1383-5718(14)00099-0 [pii] LID - 10.1016/j.mrgentox.2014.04.005 [doi] AB - Angiotensin II receptor blockers (ARBs) are a new class of drugs for the treatment of hypertension. In this study, we studied the potential genotoxic effects of five ARBs in vivo and in vitro in human peripheral blood lymphocytes (PBLs) by means of the cytokinesis-block micronucleous (CBMN) assay in combination with fluorescence in situ hybridization (FISH) with a centromeric probe. The nuclear division index (NDI) was used as a measure of cytotoxicity. We also analyzed the association between sex, age, duration of treatment and MN formation. The in vivo study was carried out in 55 hypertensive patients. The in vitro study was performed in 10 control individuals by adding the drugs to the culture medium at a final concentration similar to the levels found in plasma in patients. Our results showed a significant increase in the frequencies of MN and binucleated cells with MN (BNMN) in vivo and especially in vitro. We observed variability in the mean frequency of MN and BNMN among the five drugs analyzed. In vivo, patients treated with Candesartan, Telmisartan and Valsartan showed a statistical significant increase in these parameters, while Olmesartan showed the highest effect in vitro. We also found that the drugs inhibit the NDI in vitro and that Eprosartan, Olmesartan and Telmisartan are the ARBs studied with the highest effect in decreasing the proliferation of the cells. FISH analysis revealed no significant difference between patients and controls in the frequency of centromeric signals. A slight variability, without statistical significance, in the frequency of micronuclei with a centromere signal (CN(+)MN) was found among the different ARBs analyzed, ruling out an aneugenic potential. When accounting for risk factors, we found that in patients there is a positive correlation between MN, BNMN and sex and a negative correlation with duration of treatment. CI - Copyright (c) 2014 Elsevier B.V. All rights reserved. FAU - Huerta, Iratxe AU - Huerta I AD - Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Bilbao, Spain; Genetic Laboratory, Bilbao, Spain. FAU - Barasoain, Maitane AU - Barasoain M AD - Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Bilbao, Spain. FAU - Telez, Mercedes AU - Telez M AD - Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Bilbao, Spain; Genetic Laboratory, Bilbao, Spain. FAU - Longa, Mikel AU - Longa M AD - Virgen de Begona Laboratories (Medikosta), Erandio, Bizkaia, Spain. FAU - Muga, Javier AU - Muga J AD - Virgen de Begona Laboratories (Medikosta), Erandio, Bizkaia, Spain. FAU - Barrenetxea, Gorka AU - Barrenetxea G AD - Department of Medical-Surgical Specialties, Faculty of Medicine, University of the Basque Country, Bilbao, Spain. FAU - Ortiz-Lastra, Eduardo AU - Ortiz-Lastra E AD - Department of Medical-Surgical Specialties, Faculty of Medicine, University of the Basque Country, Bilbao, Spain. FAU - Gonzalez, Javier AU - Gonzalez J AD - Department of Medical-Surgical Specialties, Faculty of Medicine, University of the Basque Country, Bilbao, Spain. FAU - Criado, Begona AU - Criado B AD - Cooperativa de Ensino Superior Politecnico e Universitario (CESPU), Porto, Portugal. FAU - Arrieta, Isabel AU - Arrieta I AD - Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Bilbao, Spain. Electronic address: mariaisabel.arrieta@ehu.es. LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140419 PL - Netherlands TA - Mutat Res Genet Toxicol Environ Mutagen JT - Mutation research. Genetic toxicology and environmental mutagenesis JID - 101632149 RN - 0 (Angiotensin Receptor Antagonists) SB - IM MH - Aged MH - Angiotensin Receptor Antagonists/*adverse effects/pharmacology MH - Cell Proliferation/*drug effects MH - Cells, Cultured MH - Centromere/metabolism/pathology MH - *DNA Damage MH - Female MH - Humans MH - Hypertension/drug therapy/metabolism MH - In Situ Hybridization, Fluorescence MH - Leukocytes, Mononuclear/*metabolism/pathology MH - Male MH - Micronuclei, Chromosome-Defective/*chemically induced MH - Middle Aged OTO - NOTNLM OT - Angiotensin II receptor blockers OT - FISH OT - Genotoxicity OT - Micronuclei EDAT- 2014/04/24 06:00 MHDA- 2014/12/15 06:00 CRDT- 2014/04/24 06:00 PHST- 2014/01/15 00:00 [received] PHST- 2014/04/03 00:00 [revised] PHST- 2014/04/10 00:00 [accepted] PHST- 2014/04/24 06:00 [entrez] PHST- 2014/04/24 06:00 [pubmed] PHST- 2014/12/15 06:00 [medline] AID - S1383-5718(14)00099-0 [pii] AID - 10.1016/j.mrgentox.2014.04.005 [doi] PST - ppublish SO - Mutat Res Genet Toxicol Environ Mutagen. 2014 Jun;767:1-7. doi: 10.1016/j.mrgentox.2014.04.005. Epub 2014 Apr 19.